Singapore, July 12 -- CEPI, the Coalition for Epidemic Preparedness Innovations, has announced the expansion of its partnership with Sichuan Clover Biopharmaceuticals, Inc (China) to rapidly advance the development and manufacture of Clover's protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover's proprietary Trimer-Tag(c) vaccine technology platform.

CEPI will make an additional investment of $66 million upfront in S-Trimer which will immediately fund preclinical studies, the execution of Phase 1 clinical trials, and preparation of sites globally for an efficacy trial. In parallel, this investment will support scale up of Clover's manufacturing capacity to potentially allow the production of hundreds of millions of...